AUTHORS
Reed Friend, MD, Levi Pederson, MS2, Susan Geyer, PhD3, Diane Kennedy, BS4, Jill Zitzewitz, PhD5, Emily Semmel, MS6, Peyton Schumacher7, Travis Dockter, MS8, Shandra James, DNP9, Aaron S Rosenberg, MD10, Shambavi Richard, MD11, Hamza Hashmi, M.D.12, Venkatesh Charya, MS13, Jiefu Wang, PhD14, Rebecca Munsch, MHA15, Francis Baudi, MD, MBChB16, Jodi Lipof, MD17, Poy Theprungsirikul, MD18, Samuel Rubinstein, MD MSCI19, Ajay K Nooka, MD, MPH20, Anita D'Souza Jr, MD21, Kenneth Anderson, MD22, Craig Cole I, MD23, William Wood, MD, MPH24, Saad Z. Usmani, MD25, Shaji Kumar, MD26, Manisha Bhutani, MD27
AFFILIATIONS
1 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
2 Mayo Clinic, Rochester, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Rochester, Minnesota, United States
4 ASH Research Collaborative, Washington, District of Columbia, United States
5 ASH Research Collaborative, Washington, District of Columbia, United States
6 ASH Research Collaborative, Washington, District of Columbia, United States
7 Mayo Clinic, Rochester, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Rochester, Minnesota, United States
9 ASH Research Collaborative, Washington, District of Columbia, United States
10 University of California, Davis School of Medicine, Sacramento, California, United States
11 Icahn School of Medicine at Mount Sinai, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
14 University of California, Davis School of Medicine, Sacramento, California, United States
15 Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States
16 Mayo Clinic, Rochester, Rochester, Minnesota, United States
17 University of California, San Francisco, San Francsico, California, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
20 Emory University School of Medicine, Atlanta, Georgia, United States
21 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
23 Karmanos Cancer Center, Detroit, Michigan, United States
24 University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
25 Memorial Sloan Kettering Cancer Center, New York, New York, United States
26 Mayo Clinic, Rochester, Rochester, Minnesota, United States
27 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, North Carolina, United States
ABSTRACT
Introduction: Multiple myeloma (MM) is predominantly a disease of older adults, yet patients aged ≥70 years remain underrepresented in clinical trials, creating uncertainty about frontline management and subsequent-line access. We characterized frontline (L1) treatment patterns, response depth, and outcomes among older adults with MM in the ASH Research Collaborative (ASH RC) Data Hub.
Methods: Data were extracted from the ASH RC Data Hub from 2007 to 2025 with a freeze date of May 27, 2026, which includes electronic case report form data from 12 US academic medical centers. Patients aged ≥70 years with MM initiating L1 therapy were grouped by age (70-74, 75-79, ≥80). Baseline characteristics, documented L1 treatment course, L1 component exposure, best response, receipt of second line therapy (L2), TTNT, PFS, and OS were summarized. Modifications to L1 regimen including dose reduction were not considered a new treatment line. Variables were compared using chi-square, and Kruskal-Wallis tests; TTNT, PFS and OS were estimated by Kaplan-Meier methods and compared using log-rank tests stratified by institution.
Results: Of 1,076 MM patients ≥ 70 years, 631 were evaluable, of whom 380 were aged 70-74, 180 were 75-79, and 71 were ≥80 years at diagnosis; median age was 74.1 years and 53.6% were male. Median follow up was 54.7 months. The cohort was 75.5% non-Hispanic White, 18.7% non-Hispanic Black, and 2.5% Hispanic. R-ISS stage III was reported in 19.9% of 361 patients with evaluable staging. Among 477 patients with evaluable cytogenetics 15.3% met modified 2025 IMS/IMWG high-risk criteria (Avet-Loiseau, JCO 2025), similar across age groups (14.1%, 17.3%, 16.4%). The most common documented L1 treatment courses were bortezomib, lenalidomide, dexamethasone (VRd, 38.9%), daratumumab-VRd (DVRd, 16.0%), bortezomib, cyclophosphamide, dexamethasone (VCd, 10.1%), daratumumab, lenalidomide, dexamethasone (DRd, 7.8%), carfilzomib, lenalidomide, dexamethasone (KRd, 6.3%), and lenalidomide, dexamethasone (Rd, 6.7%). Across ages 70-74, 75-79, and ≥80, quadruplet L1 therapy was seen in 25.3%, 14.2%, and 12.7%, L1 proteasome inhibitor exposure was 93.2%, 82.2%, and 66.2% (p<.0001); anti-CD38 monoclonal antibody exposure was 30.0%, 30.6%, and 52.1% (p=0.001); immunomodulatory drug (IMiD) exposure was 85.5%, 83.9%, and 81.7% (p=0.68); and L1 that included autologous stem cell transplant was 40.3%, 16.7%, and 1.4% (p<.0001). The higher anti-CD38 exposure in the ≥80 group likely reflects preferential use of proteasome inhibitor–sparing regimens such as DRd in the oldest patients. VGPR or better was achieved in 76.4%, 70.0%, and 62.3% (p=0.035), and CR or better in 37.5%, 30.0%, and 18.8% (p=0.10).
347 patients (55.0%) proceeded to L2, while 284 (45.0%) had no recorded subsequent line of therapy. Among patients without a recorded L2, 74 of 284 (26.1%) had a L1 end date reported (70-74, n=35; 75-79, n=30; ≥80, n=9); of these, 15 of 74 (20.3%) have died. Median TTNT was 40.2 months (95% CI, 33.8-44.9), 48.3 months (95% CI, 35.9-60.9), and 32.0 months (95% CI, 22.1-52.9) across ages 70-74, 75-79, and ≥80, respectively (p=0.57). Median PFS was 49.0 months (95% CI, 44.5-58.4), 55.5 months (95% CI, 35.3-70.3), and 47.3 months (95% CI, 37.9-54.7), respectively (p=0.3819). Median OS was 107.3 months (95% CI, 98.8-NE), 99.9 months (95% CI, 98.1-146.9), and 73.1 months (95% CI, 54.7-NE), respectively (p=0.027; HR for ≥80 vs 70-74, 2.04; 95% CI, 1.20-3.48).
Conclusions: In this real-world cohort of older adults with MM, L1 component exposure varied significantly by age, with lower proteasome inhibitor exposure and transplant use, higher anti-CD38 exposure, and lower rates of CR and VGPR or better in patients aged ≥80. TTNT and PFS did not differ significantly by age, whereas OS was significantly shorter in the ≥80 cohort. These real-world findings reflect inferior outcomes compared to landmark phase 3 trials, highlighting the need for novel frontline strategies for older patients with MM.
DISCLOSURES
Reed Friend, MD: BMS - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)